



1845
#13


PATENT
ATTORNEY DOCKET NO. 01948/074002

Certificate of Mailing: Date of Deposit: October 30, 2002

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Moya Kinnealey

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark A. Exley et al.

Art Unit: 1645

Serial No.: 09/885,768

Examiner: Not Yet Assigned

Filed: June 19, 2001

Customer No.: 21559

Title: Compositions and Methods of Monoclonal and Polyclonal Antibodies Specific for T Cell Subpopulations

Assistant Commissioner For Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is information included in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

Please apply any charges or credits to Deposit Account 03-2095.

Date: October 30, 2002

Respectfully submitted,


Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

W:\PTO Forms New for 2001\Information Disclosure Statement.wpd

RECEIVED

NOV 07 2002

TECH CENTER 1600/2900



21559

PATENT TRADEMARK OFFICE



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	01948/074002		
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	09/885,768		
		(37 C.F.R. §1.98(b))		Applicant	Mark A. Exley et al.		
				Filing Date	June 19, 2001		
				Group	1645		
				Customer No.	21559		
				IDS Filed	October 30, 2002		
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)
	EP 0 677 533 A	18 Oct. 1995	EPO				No
	EP 1 025 854 A	9 August 2000	EPO				Yes (abstract)
	WO 99/34209	8 July 1999	WIPO				No
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Exley et al., "CD161 (NKR-P1A) Costimulation of CD1d-dependent Activation of Human T Cells Expressing Invariant Va24JaQ T Cell Receptor α Chains," <i>J. Exp. Med.</i> 188(5):867-876 (1998).						
	Nicol et al., "Human Invariant Va24 $^{+}$ Natural Killer T Cells Activated By α -galactosylceramide (KRN7000) Have Cytotoxic Anti-tumour Activity Through Mechanisms Distinct From T Cells And Natural Killer Cells," <i>Immunology</i> 99:229-234 (2000).						
	Wilson et al., "Development of Monoclonal Antibodies to Va24JaQ T Cells Detects Alterations In Cell Frequency In New-Onset Type 1 Diabetes Patients," <i>Diabetes</i> vol. 50, Supplement 2 (2001).						
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							

RECEIVED
NOV 07 2002
TECH CENTER 1600/2900